Valgen Medtech developed MitralStitch, China’s first transapical device for the treatment of mitral regurgitation, DragonFly-M, China’s first transfemoral mitral valve repair device, and DragonFly-T, China’s first transfemoral tricuspid valve repair device. Currently, Mitralstitch and DragonFly have entered pre-marketing registered clinical trials. In particular, the DragonFly transcatheter mitral valve clip system fills the gap in transfemoral mitral valve treatment devices in China, putting Chinese players on the same level as top international brands in the R&D of interventional mitral valve devices.
In May 2020, Venus Medtech announced its investment in Valgen Holding Corporation, a leading company in mitral valve treatment technologies and systemic solutions, in order to consolidate its mitral valve repair product and tricuspid valve repair product pipelines and further improve the strategic blueprint for structural heart disease treatment. Venus Medtech now has a mitral valve replacement device (Limbus) in exploratory clinical trial preparation stage and a tricuspid valve replacement device in R&D. The investment in Valgen Medtech will create synergy with Venus Medtech’s existing product layout in the treatment of mitral and tricuspid disease to provide more innovative treatments for doctors and patients worldwide.